Latest Business News
Eli Lilly's Experimental Drug Shows Highest Reduction in Obesity Treatment Space History
Mid-Stage Clinical Trial Results
New mid-stage clinical trial results revealed that Eli Lilly's experimental drug showed a loss of up to 24% of the weight in patients, which is the highest reduction ever seen in the obesity treatment space. The trial was carried out on 338 overweight or obese adults who were injected with the pharmaceutical company's injection, retatrutide, or a placebo each week.
Weight Loss Data
Patients who received a 12-milligram dose of retatrutide reportedly lost 17.5% of their body weight, which is around 41 pounds on average after 24 weeks, whereas patients who received a placebo lost only 1.6% of their body weight. The study also showed that patients lost an average of 24.2%, or 58 pounds, after 48 weeks. On the other hand, those who took the placebo lost only 2.1% of their body weight during the same time period.
Longer Studies May Show More
According to the researchers, the average weight loss did not appear to plateau at the end of 48 weeks, suggesting that longer studies could show even more substantial weight loss. Therefore, Eli Lilly is now recruiting patients for a phase three trial. Michael Weintraub, an endocrinologist at NYU Langone Health, said in a Twitter post that this data suggests Eli Lilly's retatrutide is the "most effective anti-obesity med to date."
Comparison With Other Obesity Drugs
Eli Lilly's other obesity drug Mounjaro, which is used to treat type 2 diabetes, has helped patients lose up to 21% of their weight in clinical trials. Wegovy, which is cleared for weight loss from Novo Nordisk, has shown up to 15% of weight loss in trials. While all three drugs are weekly injections that change the way patients eat and lead to decreased appetite by mimicking certain hormones in the gut, Retatrutide mimics three different hunger-regulating hormones: GLP-1, GIP, and glucagon. This seems to have more potent effects on a person's appetite and satisfaction with food.
The mid-stage clinical trial results revealing Eli Lilly's experimental drug, retatrutide, to be the most effective anti-obesity drug to date, is a game-changer for the obesity treatment space. Patients who received a 12-milligram dose of the drug lost 17.5% of their body weight, which is equivalent to around 41 pounds on average after a 24-week period. This is compared to a mere 1.6% of weight loss for placebo patients. With this impressive weight loss data and the potential for even more substantial weight loss following longer studies, Eli Lilly is recruiting patients for a phase three trial.
This news could have a significant impact on a new business focused on developing treatments for obesity. While there are other weekly-injected drugs on the market for weight loss, they have shown less impressive results, with the highest weight loss percentage being 21%. The potency of Retatrutide on a patient's appetite and satisfaction with food makes it stand out from competitors. A pharmaceutical company focused on obesity treatment can use this information to advance their research and development, with a goal to create an equally effective or superior drug to Retatrutide to attract the growing number of consumers looking for an efficient way to manage their weight.